PT1423124E - Formulação liofilizada de 2 metil-tieno-benzodiazepina - Google Patents
Formulação liofilizada de 2 metil-tieno-benzodiazepina Download PDFInfo
- Publication number
- PT1423124E PT1423124E PT02749634T PT02749634T PT1423124E PT 1423124 E PT1423124 E PT 1423124E PT 02749634 T PT02749634 T PT 02749634T PT 02749634 T PT02749634 T PT 02749634T PT 1423124 E PT1423124 E PT 1423124E
- Authority
- PT
- Portugal
- Prior art keywords
- formulation
- olanzapine
- dsm
- pages
- disorders
- Prior art date
Links
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims description 78
- 229960005017 olanzapine Drugs 0.000 title claims description 77
- 239000012931 lyophilized formulation Substances 0.000 title description 12
- 239000000203 mixture Substances 0.000 claims description 68
- 238000009472 formulation Methods 0.000 claims description 62
- 206010001497 Agitation Diseases 0.000 claims description 28
- 238000013019 agitation Methods 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 23
- 239000011975 tartaric acid Substances 0.000 claims description 23
- 235000002906 tartaric acid Nutrition 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 229960001021 lactose monohydrate Drugs 0.000 claims description 15
- 229960001375 lactose Drugs 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 206010026749 Mania Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000012826 adjustment disease Diseases 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 208000022821 personality disease Diseases 0.000 claims description 4
- 150000003892 tartrate salts Chemical class 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 230000000506 psychotropic effect Effects 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000031091 Amnestic disease Diseases 0.000 claims description 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 2
- 230000006986 amnesia Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 238000004108 freeze drying Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003125 aqueous solvent Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 230000001755 vocal effect Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- NFEUHAIRXOEOTJ-LREBCSMRSA-N (2R,3R)-2,3-dihydroxybutanedioic acid 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine Chemical compound O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 NFEUHAIRXOEOTJ-LREBCSMRSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010020400 Hostility Diseases 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005032 impulse control Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- -1 olanzapine Chemical class 0.000 description 1
- 229940080131 olanzapine 10 mg Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30682901P | 2001-07-20 | 2001-07-20 | |
| US38647402P | 2002-06-07 | 2002-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1423124E true PT1423124E (pt) | 2007-10-29 |
Family
ID=26975390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02749634T PT1423124E (pt) | 2001-07-20 | 2002-07-05 | Formulação liofilizada de 2 metil-tieno-benzodiazepina |
Country Status (32)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7323459B2 (en) * | 2002-12-24 | 2008-01-29 | Teva Pharmaceutical Industries Ltd. | Crystal forms, methods for their preparation and method for preparation of olanzapine |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
| ATE504588T1 (de) | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| WO2006076124A2 (en) * | 2004-12-16 | 2006-07-20 | Nektar Therapeutics | Stable, non-crystalline formulation comprising olanzapine |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
| EP3735223A4 (en) * | 2018-01-05 | 2021-10-13 | Impel Neuropharma Inc. | INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE |
| PE20212195A1 (es) * | 2019-03-01 | 2021-11-15 | Eurofarma Laboratorios S A | Composicion farmaceutica liofilizada de antiinflamatorio no esteroideo |
| HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
| CN115006406A (zh) * | 2021-12-28 | 2022-09-06 | 南京清普生物科技有限公司 | 一种稳定的奥氮平制剂 |
| WO2025056094A1 (zh) * | 2023-09-15 | 2025-03-20 | 广州帝奇医药技术有限公司 | 一种冻干制剂和注射液及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0421297T3 (da) * | 1989-09-30 | 1994-01-17 | Eisai Co Ltd | Injicerbare præparater indeholdende cephalosporin som lægemiddel og anvendelse deraf |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
2002
- 2002-05-07 UA UA2004010428A patent/UA80095C2/uk unknown
- 2002-07-05 WO PCT/US2002/019799 patent/WO2003007912A2/en not_active Ceased
- 2002-07-05 EA EA200400211A patent/EA006506B1/ru not_active IP Right Cessation
- 2002-07-05 SI SI200230629T patent/SI1423124T1/sl unknown
- 2002-07-05 EP EP02749634A patent/EP1423124B1/en not_active Expired - Lifetime
- 2002-07-05 BR BR0211250-7A patent/BR0211250A/pt not_active IP Right Cessation
- 2002-07-05 PT PT02749634T patent/PT1423124E/pt unknown
- 2002-07-05 DE DE60221674T patent/DE60221674T2/de not_active Expired - Lifetime
- 2002-07-05 AU AU2002320134A patent/AU2002320134B2/en not_active Expired
- 2002-07-05 KR KR10-2004-7000829A patent/KR20040017330A/ko not_active Ceased
- 2002-07-05 PL PL02366614A patent/PL366614A1/xx not_active Application Discontinuation
- 2002-07-05 CZ CZ200484A patent/CZ200484A3/cs unknown
- 2002-07-05 CA CA002448724A patent/CA2448724A1/en not_active Abandoned
- 2002-07-05 IL IL15909802A patent/IL159098A0/xx unknown
- 2002-07-05 SK SK18-2004A patent/SK182004A3/sk unknown
- 2002-07-05 AT AT02749634T patent/ATE369137T1/de active
- 2002-07-05 JP JP2003513521A patent/JP2004537546A/ja active Pending
- 2002-07-05 ES ES02749634T patent/ES2289126T3/es not_active Expired - Lifetime
- 2002-07-05 US US10/480,617 patent/US20040176357A1/en not_active Abandoned
- 2002-07-05 DK DK02749634T patent/DK1423124T3/da active
- 2002-07-05 MX MXPA04000541A patent/MXPA04000541A/es active IP Right Grant
- 2002-07-05 NZ NZ529667A patent/NZ529667A/en not_active IP Right Cessation
- 2002-07-05 HU HU0401157A patent/HUP0401157A3/hu unknown
- 2002-07-05 HR HR20040037A patent/HRP20040037A2/hr not_active Application Discontinuation
- 2002-07-05 CN CNA028144473A patent/CN1537007A/zh active Pending
- 2002-07-17 PE PE2002000636A patent/PE20030281A1/es active IP Right Grant
- 2002-07-18 MY MYPI20022723A patent/MY135452A/en unknown
- 2002-07-18 AR ARP020102700A patent/AR036180A1/es not_active Application Discontinuation
- 2002-07-19 SV SV2002001179A patent/SV2003001179A/es not_active Application Discontinuation
-
2003
- 2003-12-31 CO CO03113784A patent/CO5540279A2/es not_active Application Discontinuation
-
2004
- 2004-01-30 ZA ZA2004/00798A patent/ZA200400798B/en unknown
-
2007
- 2007-10-11 CY CY20071101308T patent/CY1107759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU211937A9 (en) | Indole derivatives | |
| BRPI0708965B1 (pt) | Composição farmacêutica de metilnaltrexona | |
| BR112019018420A2 (pt) | composição farmacêutica que compreende selexipag | |
| EP1423124B1 (en) | Lyophilized formulation comprising olanzapine | |
| BR112013000802B1 (pt) | Forma de dispersão sólida de rifaximina, microgrânulo compreendendo a referida forma, composição farmacêutica compreendendo o referido microgrânulo e processos para a 5 produção de uma dispersão sólida de rifaximina | |
| CN102755296B (zh) | 一种含有福沙吡坦的无菌冻干制剂及其制备方法 | |
| US20060188576A1 (en) | Pirenzepine ophthalmic gel | |
| CN108135889A (zh) | 用于在危重监护治疗期间使用的镇静方法和肠胃外制剂 | |
| AU2002320134A1 (en) | Lyophilized formulation comprising olanzapine | |
| CN111848512B (zh) | 使用高纯度盐酸罂粟碱制备粉针剂药物组合物 | |
| HUP0102812A2 (hu) | Foszfolipáz inhibitor hatású nátrium-{[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1H-indol-4-il]oxi}acetátot tartalmazó gyógyászati készítmények és eljárás előállításukra | |
| WO2020248648A1 (zh) | 一种奥硝唑注射液和s-奥硝唑注射液 | |
| HK1066484B (en) | Lyophilized formulation comprising olanzapine | |
| WO2024062443A1 (en) | Pharmaceutical compositions | |
| CN111796043B (zh) | 注射用盐酸罂粟碱粉针剂及其质量检测方法 | |
| JP2001519395A (ja) | カルバマゼピンまたはその誘導体を含む非経口製剤 | |
| CN111789818A (zh) | 注射用盐酸罂粟碱药物组合物及制备方法 | |
| TWI819756B (zh) | 包含塞納布啡的藥物組合物 | |
| RU2684330C1 (ru) | Композиции фулвестранта | |
| KR20010040671A (ko) | 소뇌 기능장애 예방 또는 치료를 위한2-아미노-6-트리플루오로메톡시-벤조티아졸의 용도 | |
| CN104146971B (zh) | 注射用盐酸纳洛酮粉针剂药物组合物和制法 | |
| TW202432169A (zh) | 輔美康（degarelix）有機溶劑調配物 | |
| CN118105387A (zh) | 一种伏诺拉生氟比洛芬药物组合物及其制备方法 | |
| CN105560195A (zh) | 注射用冷冻干燥盐酸罗哌卡因组合物 |